Difference between revisions of "Lung carcinoma with EGFR mutation"
Jump to navigation
Jump to search
m (Michael moved page Lung carcinoma with EGFR rearrangement to Lung carcinoma with EGFR mutation: redirect) |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Lung | '''Lung carcinoma with EGFR mutation''' is a molecular subtype of [[lung carcinoma]]. Morphologically, these tumours are typically [[adenocarcinoma]]s. | ||
==General== | ==General== | ||
*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]]. | *Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]]. | ||
**Testing done together with ALK. | **Testing done together with ALK. | ||
*EGRF mutation excludes ALK rearrangement.<ref name=pmid23729361>{{Cite journal | last1 = Gainor | first1 = JF. | last2 = Varghese | first2 = AM. | last3 = Ou | first3 = SH. | last4 = Kabraji | first4 = S. | last5 = Awad | first5 = MM. | last6 = Katayama | first6 = R. | last7 = Pawlak | first7 = A. | last8 = Mino-Kenudson | first8 = M. | last9 = Yeap | first9 = BY. | title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. | journal = Clin Cancer Res | volume = 19 | issue = 15 | pages = 4273-81 | month = Aug | year = 2013 | doi = 10.1158/1078-0432.CCR-13-0318 | PMID = 23729361 }}</ref> | *EGRF mutation excludes [[Lung carcinoma with ALK rearrangement|ALK rearrangement]].<ref name=pmid23729361>{{Cite journal | last1 = Gainor | first1 = JF. | last2 = Varghese | first2 = AM. | last3 = Ou | first3 = SH. | last4 = Kabraji | first4 = S. | last5 = Awad | first5 = MM. | last6 = Katayama | first6 = R. | last7 = Pawlak | first7 = A. | last8 = Mino-Kenudson | first8 = M. | last9 = Yeap | first9 = BY. | title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. | journal = Clin Cancer Res | volume = 19 | issue = 15 | pages = 4273-81 | month = Aug | year = 2013 | doi = 10.1158/1078-0432.CCR-13-0318 | PMID = 23729361 }}</ref> | ||
Treatement:<ref name=pmid20887192>{{Cite journal | last1 = da Cunha Santos | first1 = G. | last2 = Shepherd | first2 = FA. | last3 = Tsao | first3 = MS. | title = EGFR mutations and lung cancer. | journal = Annu Rev Pathol | volume = 6 | issue = | pages = 49-69 | month = | year = 2011 | doi = 10.1146/annurev-pathol-011110-130206 | PMID = 20887192 }}</ref> | |||
*[[Tyrosine kinase inhibitors]]. | |||
===Associations=== | ===Associations=== | ||
| Line 55: | Line 58: | ||
*[[Lung carcinoma with ALK rearrangement]]. | *[[Lung carcinoma with ALK rearrangement]]. | ||
*[[Epidermal growth factor receptor inhibitors]]. | *[[Epidermal growth factor receptor inhibitors]]. | ||
*[[ROS1-rearranged non-small cell lung carcinoma]]. | |||
==References== | ==References== | ||
Latest revision as of 02:19, 31 December 2019
Lung carcinoma with EGFR mutation is a molecular subtype of lung carcinoma. Morphologically, these tumours are typically adenocarcinomas.
General
- Testing indicated in non-small cell carcinoma, adenosquamous carcinoma of the lung, as well as lung adenocarcinoma.
- Testing done together with ALK.
- EGRF mutation excludes ALK rearrangement.[1]
Treatement:[2]
Associations
Varies significantly by population:[3]
| Population | Prevalence | Category |
|---|---|---|
| Europe | 14% | Geographic |
| China | 38% | Geographic |
| Females | 44% | Patient characteristics |
| Males | 24% | Patient characteristics |
| Non-smokers | 49% | Patient characteristics |
| Smokers or past smokers | 22% | Patient characteristics |
| Adenocarcinoma | 38% | Pathology |
| Non-adenocarcinoma | 12% | Pathology |
Sign out
Lung core biopsy, left lower lobe: - EGFR mutation POSITIVE, ALK rearrangement NEGATIVE
See also
- Lung carcinoma with ALK rearrangement.
- Epidermal growth factor receptor inhibitors.
- ROS1-rearranged non-small cell lung carcinoma.
References
- ↑ Gainor, JF.; Varghese, AM.; Ou, SH.; Kabraji, S.; Awad, MM.; Katayama, R.; Pawlak, A.; Mino-Kenudson, M. et al. (Aug 2013). "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.". Clin Cancer Res 19 (15): 4273-81. doi:10.1158/1078-0432.CCR-13-0318. PMID 23729361.
- ↑ da Cunha Santos, G.; Shepherd, FA.; Tsao, MS. (2011). "EGFR mutations and lung cancer.". Annu Rev Pathol 6: 49-69. doi:10.1146/annurev-pathol-011110-130206. PMID 20887192.
- ↑ Zhang, YL.; Yuan, JQ.; Wang, KF.; Fu, XH.; Han, XR.; Threapleton, D.; Yang, ZY.; Mao, C. et al. (Nov 2016). "The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.". Oncotarget 7 (48): 78985-78993. doi:10.18632/oncotarget.12587. PMID 27738317.